Drug Trial Radar · NCT02766621
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
Last checked: Nov 20, 2026Latest source record: Nov 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
May 27, 2016
Primary completion
Aug 30, 2017
Study completion Sep 26, 2017
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of escalating single and multiple intravenous (IV) infusions and subcutaneous (SC) injections of PF 06823859 in healthy subjects.
Conditions
- Healthy
Interventions
PF-06823859Biological
Comparison of different dosages of PF-06823859 to placebo
Placebo injection SC/IVDrug
Comparison of Placebo to different doses of PF-06823859
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEsTime frame: Dosing through approximately Day 189
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer New Haven Clinical Research Unit
New Haven, Connecticut
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.